Kiadis Pharma Terug naar discussie overzicht

Kiadis Pharma - 4e kwartaal 2019

1. DeZwarteRidder 18 december 2019 16:08

   auteur info

   • DeZwarteRidder

     Lid sinds: 29 jun 2012

     Laatste bezoek: 19 apr 2024

   • Aanbevelingen

     Ontvangen: 20760

     Gegeven: 9428

   •    Aantal posts: 96.617

   quote:

   Rendiertje schreef op 18 december 2019 16:04:

   we gaan inderdaad de weg naar de 3 euro maken.
   

   Het wordt hoog tijd voor een competitie: 'Wanneer staat de koers op 2 euro'.
2. [verwijderd] 18 december 2019 16:34

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   DeZwarteRidder schreef op 18 december 2019 16:08:

   [...]
   Het wordt hoog tijd voor een competitie: 'Wanneer staat de koers op 2 euro'.
   

   Beter: waar staat de koers na sluiting van de beurs op, pak hem beet, 10 Januari 2020?
   Dat is een vrijdag.
3. Diesel. 18 december 2019 16:41

   auteur info

   • Diesel.

     Lid sinds: 15 nov 2017

     Laatste bezoek: 14 aug 2022

   • Aanbevelingen

     Ontvangen: 110

     Gegeven: 38

   •    Aantal posts: 732

   quote:

   gokker schreef op 18 december 2019 16:34:

   [...]
   
   Beter: waar staat de koers na sluiting van de beurs op, pak hem beet, 10 Januari 2020?
   Dat is een vrijdag.
   

   10 januari sluiting beurs 3,05
4. [verwijderd] 18 december 2019 16:48

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   ik gok op 3.20 EUR slot op 10 januar
   
   dus:
   
   3.20 Rendiertje
   3.05 Diesel
5. [verwijderd] 18 december 2019 16:52

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   1.74 op 10 januari.
6. [verwijderd] 18 december 2019 16:59

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   quote:

   Alalalonglong schreef op 18 december 2019 16:52:

   1.74 op 10 januari.
   

   Dit maakt natuurlijk alleen maar zin wanneer er een tijd wordt afgesproken waarop op zijn laatst een bedrag genoemd mag worden. Dit lijkt me een prima opgave voor het rendier!
7. Dick123 18 december 2019 17:27

   auteur info

   • Dick123

     Lid sinds: 12 jul 2013

     Laatste bezoek: 24 jul 2023

   • Aanbevelingen

     Ontvangen: 295

     Gegeven: 5

   •    Aantal posts: 1.661

   Velen roepen groen, maar het valt of staat met een melding dat er een samenwerking komt met een groot biobedrijf. Een constructie ala galapagos zou niet verkeerd zijn, of dit voor de kerst gaat lukken blijft de vraag. Mijn inziens is dit onmogelijk omdat er vele overleggen plaats moeten vinden alvorens men tot een dergelijk besluit komt.
8. [verwijderd] 18 december 2019 18:19

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Morgen dus hoger.
9. ff_relativeren 18 december 2019 18:29

   auteur info

   • ff_relativeren

     Lid sinds: 05 mrt 2013

     Laatste bezoek: 24 jul 2022

   • Aanbevelingen

     Ontvangen: 6944

     Gegeven: 5207

   •    Aantal posts: 25.963

   quote:

   gokker schreef op 18 december 2019 16:34:

   [...]
   
   Beter: waar staat de koers na sluiting van de beurs op, pak hem beet, 10 Januari 2020?
   Dat is een vrijdag.
   

   Ik doe mee ! Mijn voorspelling voor de beurskoers op 10 januari 2020 nabeurs :
   
   Op een gemiddelde daling per dag van € 0,02 en nog pakweg 13 handelsdagen te gaan tot en met 10 januari 2020, gaat er theoretisch nog 13 X € 0,02 = € 0,26 van de beurskoers af.
   
   € 2,12 -/- € 0,26 = € 1,86. Gents, ik rond het af op een slotstand van € 1,85.
   
10. ff_relativeren 18 december 2019 18:32

    auteur info

    • ff_relativeren

      Lid sinds: 05 mrt 2013

      Laatste bezoek: 24 jul 2022

    • Aanbevelingen

      Ontvangen: 6944

      Gegeven: 5207

    •    Aantal posts: 25.963

    quote:

    DeZwarteRidder schreef op 18 december 2019 16:08:

    [...]
    Het wordt hoog tijd voor een competitie: 'Wanneer staat de koers op 2 euro'.
    

    Over 6 handelsdagen, nabeurs. (want een gemiddelde daling van € 0,02 per handelsdag) Eerder kan ook.
11. [verwijderd] 18 december 2019 18:44

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Dick123 schreef op 18 december 2019 17:27:

    Velen roepen groen, maar het valt of staat met een melding dat er een samenwerking komt met een groot biobedrijf. Een constructie ala galapagos zou niet verkeerd zijn, of dit voor de kerst gaat lukken blijft de vraag. Mijn inziens is dit onmogelijk omdat er vele overleggen plaats moeten vinden alvorens men tot een dergelijk besluit komt.
    

    Er is al lijkt me overleg daarom is het ook waarschijnlijk dat de grotere beleggers blijven zitten.
    We gaan dat zien binnenkort in dit theater
12. [verwijderd] 18 december 2019 19:19

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kiadis on BNR newsradio
    
    www.bnr.nl/player/audio/10074268/1033...
13. [verwijderd] 18 december 2019 19:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    kiadis timmert aan de weg met o.a. een project manager er staan nu 3 vacatures open 1 ervan zie hier onder.
    
    At Kiadis, we are leveraging the natural strengths of humanity and our collective immune systems to source the best cells for life. When it comes to life-threatening diseases, we are one family. Fully focused on cell therapies in immuno-oncology, our NK cell (natural killer cell) research and development programs and partnerships are at the cutting-edge of the industry, paving the way for a new and exciting scientific field.
    
    In support of developing our innovative NK cell therapies, we are looking for a Project Manager – NK Cell Program, home-based in the United States (ideally the Seattle area).
    
    The role
    
    As the Project Manager, you will drive and facilitate an integrated project plan to serve the fast product development of our NK therapies. You’ll work closely with our cross-functional R&D team members, which will give each day a new dynamic. Your greatest achievement will be getting to all milestones, targets and registration dates in an effective and efficient manner. Day to day you will:
    
    Develop, track and manage development program timelines, resource and budget allocations, deliverables and milestone progress, including critical path dependencies and activities;
    Help identify risks, risk mitigation and escalations needed to address key issues.
    Prepare status reports for the senior management team and product development team in a synthesized manner. Includes ongoing feedback/metrics to improve the review process. Manage the review calendars and agendas for phase/stage reviews;
    Prepare management reviews action items and follow-up to ensure completion; Ensure compound strategy and project management documents are clear, complete, current and stored appropriately;
    Co-manage day-to-day operational aspects of project sub-teams to ensure progress according to budget and timelines; Support teams in critical meetings; Drive coordination across teams.
    At request of management team, support business development / commercial teams to assemble business cases for external research collaboration and L&A projects and prepare summary of the information for portfolio review.
    
    The ideal candidate
    
    We are looking for someone with great influencing and communication skills, and intercultural sensitivity. You are able to combine being service oriented with driving for results. You also possess the following requirements:
    
    Advanced degree in a life science discipline, or equivalent by experience.
    At least 10 years of relevant experience in pharma/biotech product development, of which at least 5 years in project management/PMO.
    Excellent knowledge of project management tools, including principles of critical path analysis, strategic planning, risk management, conflict resolution, negotiation skills, budgeting and project costing.
    Knowledge and understanding of pharmaceutical regulations in Biologics and/or ATMP guidelines is required.
    Fluency in English, other languages are a plus.
    Travel up to 20-25%, within the US and internationally
    
    What we offer
    
    A challenging position in an innovative biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization.
    
    You will be rewarded with a competitive remuneration package, the opportunity for personal development and to contribute to making a huge difference for patients.
14. [verwijderd] 18 december 2019 19:25

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We are Kiadis, when it comes to life-threatening diseases, we are one family. Kiadis is leveraging the natural strengths of human immune systems to source the best cells to produce innovative therapies for life-threatening disease. We are focused on NK cell research & development to maximize the potential of NK cell therapeutics. Kiadis is a leader in creating cutting-edge science in the exciting and emerging fields of cell therapy and immuno-oncology.
    
    In support of developing our innovative NK cell therapies, we are looking for a Research Technician/Research Associate based in Amsterdam, the Netherlands. All levels of Research Technicians will be considered, commensurate with skills, training level and experience.
    
    The role
    
    As a Research Technician, you are an important member of our integral research team. You’ll work form our state-of-the-art laboratory in Amsterdam and help to conduct immunological laboratory research studies. Focused to further fuel innovation in our current pipeline and to assist us reaching our goal: helping patients in need. Day to day you will:
    
    Be responsible for executing laboratory experiments for development of NK cell therapeutics.
    Document experiments, analyse results and produce research reports.
    Work collaboratively with the Scientists and VP of Discovery to conduct research directed at developing new therapeutics.
    When required, interact with other members of the Research Team.
    
    The ideal candidate
    
    We are looking for capable Research Technicians who have experience in mammalian cell culture methods, genomic analysis, DNA molecular biology methods and flow cytometry methods. As you are not only spending your time around NK-cells but also around people, we are looking for someone that likes to work in a team. You are honest and open, and believe clear communication helps in the process to develop great research. You also possess the following requirements:
    
    Advanced degree (BSc or MSc) in cell biology, immunology, biochemistry or related field.
    The technician will have a 2-5 years of laboratory research experience. Experience is desirable in cell culture, flow cytometry, biochemical assays, gel electrophoresis, and basic life science research.
    Experience in general life science research method, ideally in T- or NK-cell biology is preferred, or related.
    Some experience in working with other technicians and scientists as part of an integral research team.
    Fluency in English, other languages are a plus.
    
    What we offer
    
    A challenging position in an innovative biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization.
    
    You will be rewarded with a competitive remuneration package, the opportunity for personal development and to contribute to making a huge difference for patients.
    
    Contact the job poster
    Job poster profile
    Jenny Passos 2nd
    Senior Specialist Talent Acquisition & Employer Branding
    
    Job Poster Location
    Bullewijk, Amstel III, North Holland Province, Netherlands
    
    Send InMail
    Seniority Level
    Mid-Senior level
    
    Industry
    Biotechnology
    Employment Type
    Full-time
    
    Job Functions
    
15. [verwijderd] 18 december 2019 19:25

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We are Kiadis, when it comes to life-threatening diseases, we are one family. Kiadis is leveraging the natural strengths of human immune systems to source the best cells to produce innovative therapies for life-threatening disease. We are focused on NK cell research & development to maximize the potential of NK cell therapeutics. Kiadis is a leader in creating cutting-edge science in the exciting and emerging fields of cell therapy and immuno-oncology.
    
    In support of developing our innovative NK cell therapies, we are looking for a Scientist at various levels to be based in Amsterdam, the Netherlands. All seniority levels of the Scientist will be considered, commensurate with skills, training level and experience.
    
    The role
    
    As a Scientist, you are an important member of our integral research team. You’ll work in our state-of-the-art laboratory in Amsterdam and will conduct studies to develop our near clinical NK cell therapeutics. Focused to further fuel innovation in our current pipeline and to assist us reaching our goal: helping patients in need. Day to day you will:
    
    Be responsible for conducting experimental studies to identify optimal mechanisms for creating more potent NK cell therapeutics. Conduct laboratory studies for determining sources for NK cells with optimal profiles and related biology.
    Manage interactions with technicians and other research colleagues.
    Work collaboratively with the VP of Discovery and the CSO defining the scientific research directed at developing new therapeutics.
    Work integrally for cross-functional interactions with and support Clinical Immunology, Process Development and Clinical Development teams.
    
    The ideal candidate
    
    We are looking for someone with a PhD in NK cell biology, T cell biology, immunology, immune-oncology or related field. You are someone that has good scientific training, thinks innovatively for development of immunological therapies, and combines this with excellent communication skills to the rest of the research team and to Kiadis. Ideally, you work well with technicians as part of an integral research team. Ideally, your scientific experience or expertise aligns with the scenarios/descriptions below:
    
    Scenario 1
    
    You will be a key scientist to develop NK cell therapeutics that rely on expertise of HLA-KIR biology for NK cell activity. You understand “missing self” and how to utilize such concepts for development of Off-the-Shelf NK cell therapies.
    You have a detailed understanding of how NK cells recognize tumor targets and then trigger cytotoxicity toward targets. The ideal scientist will understand of KIR signaling.
    
    Scenario 2
    
    You will conduct studies to develop NK cell therapeutics that rely on novel stimulatory methods to modulate activity and proliferation of NK cells. You understand activating and inhibitory mechanisms of NK cells and how to utilize such concepts for development of NK cell therapies.
    You have a detailed understanding of the receptor biology of NK cells to stimulate or inhibit key pathways that then trigger cytotoxicity toward targets. An expert who has experience studying intracellular signaling will be ideal.
    
    Scenario 3
    
    You will conduct studies to develop NK cell therapeutics that rely on novel gene modifications that enhances activities of NK cells. You have experience with molecular biology for gene modification of NK cells and how to utilize such methods for development of NK cell therapies.
    You have a detailed understanding of various gene modification methods (CRISPR, lentiviral methods, transposon methods) that could be used to enhance functionality of NK cell therapeutics. An expert who has experience modifying primary cells will be ideal.
    
    What we offer
    
    A challenging position in an innovative biotechnology company. Working in a fast-paced dynamic environment brings the opportunity to make your own mark within the organization.
    
    You will be rewarded with a competitive remuneration package, the opportunity for personal development and to contribute to making a huge difference for patients.
16. ff_relativeren 18 december 2019 19:30

    auteur info

    • ff_relativeren

      Lid sinds: 05 mrt 2013

      Laatste bezoek: 24 jul 2022

    • Aanbevelingen

      Ontvangen: 6944

      Gegeven: 5207

    •    Aantal posts: 25.963

    Wie wil er nu werken voor een bedrijf dat over enkele maanden misschien geen salaris meer kan betalen ? Een emissie kan pas starten als er banken zijn gevonden die bereid zijn om de emissie te onderschrijven. En dat is nogal een risico.
17. [verwijderd] 18 december 2019 20:24

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Seven months after acquiring CytoSen Therapeutics for its NK-cell platform, Netherlands-based Kiadis Pharma announced this morning that will now be its sole developmental focus. The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.
    
    Now that the CytoSen NK-cell platform is under its umbrella, Kiadis said the off-the-shelf platform has the potential to make NK-cell therapy products rapidly and economically available for a broad patient population across a potentially wide range of indications. NK-cells are one of the body's first lines of immunological defense with an innate ability to rapidly and selectively destroy abnormal cells, such as cancer or virally-infected cells.
    
    CytoSen's lead NK-cell therapy candidate, CSDT002-NK, now known as K-NKoo2, is expected to enter clinical development in 2020. A Phase I/II study is expected to begin early next year as an adjunctive treatment to the current standard-of-care haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplant cyclophosphamide (PTCy). The phase I/II study was designed based on promising clinical proof-of-concept data in 25 patients that demonstrated a reduction of long-term relapse rates from 45% in a matched contemporaneous control of patients treated with PTCy, to 8% of patients treated with PTCy and K-NK002.
    
    Also entering the clinic next year will be K-NK003, a potential treatment for patients with relapse and refractory acute myeloid leukemia. A Phase I/IIa study will be initiated in 2020 and is based on clinical proof-of-concept data that showed a 69% complete response rate, the company said. Kiadis has multiple preclinical programs evaluating its K-NK-cell therapies for the treatment of solid tumors.
    
    Arthur Lahr, chief executive officer of Kiadis Pharma, said the company believes its NK-cell therapy platform has “broad potential as stand-alone or adjunctive treatments for patients with both liquid and solid tumors.” He said the off-the-shelf platform is based on NK-cells from unique universal donors, which have then been expanded and activated with the company’s PM21 particle technology. That has allowed for the rapid availability of the NK-cell products for patients in need, he said.
    
    “The proof-of-concept trials for our NK pipeline programs, in which 38 patients have been treated, is very promising and was the basis for our acquisition of CytoSen Therapeutics, Inc. earlier this year. To confirm findings from these trials, we will start two Phase 1/2 clinical trials in 2020. We believe that investing in our NK platform and rapidly advancing development of our off-the-shelf and haplo donor-derived NK-cell therapies in solid and liquid tumors will bring value to patients and our investors,” Lahr said in a statement.
    
    When the company reviewed its portfolio, Lahr said the company focused on its lead T-cell product and after significant analysis, determined that the current design of the Phase III trial would demonstrate superiority over the PTCy protocol.
    
    “In the best interest of patients, we have therefore taken the decision to discontinue the ATIR101 study with immediate effect and are proceeding with close down activities,” Lahr added.
    
    As a result of the new focus, Kiadis will lay off about half of its staff, a reduction in external clinical trial costs associated with the phase 3 study and a reduced company cash burn. The company ended the third quarter of 2019 with approximately €47 million in cash.
18. [verwijderd] 18 december 2019 21:03

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ff_relativeren schreef op 18 december 2019 19:30:

    Wie wil er nu werken voor een bedrijf dat over enkele maanden misschien geen salaris meer kan betalen ? Een emissie kan pas starten als er banken zijn gevonden die bereid zijn om de emissie te onderschrijven. En dat is nogal een risico.
    

    Zou haast denken hier spreekt een bitter mens. Mijn advies gewoon iets anders gaan doen.
    Dit is tussen nu en april een zware pil om te slikken.
19. ff_relativeren 18 december 2019 21:08

    auteur info

    • ff_relativeren

      Lid sinds: 05 mrt 2013

      Laatste bezoek: 24 jul 2022

    • Aanbevelingen

      Ontvangen: 6944

      Gegeven: 5207

    •    Aantal posts: 25.963

    quote:

    Break Up schreef op 18 december 2019 21:03:

    [...]
    
    Zou haast denken hier spreekt een bitter mens. Mijn advies gewoon iets anders gaan doen.
    Dit is tussen nu en april een zware pil om te slikken.
    

    Je vergist je deerlijk. Het is puur realisme, zonder een greintje bitterheid.
    Het onderschrijven van een (claim)emissie betekent voor de begeleidende banken,
    dat zij garant staan voor de koop van alle aandelen die Kiadis niet op de beurs kwijt kan.
    
    Dat is een serieus risico voor de banken. En mogelijk een obstakel voor Kiadis.
20. [verwijderd] 18 december 2019 21:13

    auteur info

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    GC Labcell has presented the preclinical trial data for new blood cancer treatment that combines its MG4101, a natural killer (NK) cell treatment, and Tafasitamab, a targeted-anticancer treatment developed by MorphoSys.
    
    The company made its presentation during the annual conference of 61st American Society of Hematology (ASH).
    
    MG4101 is an immune cell therapy that removes cancer cells by using NK cells -- innate immune cells extracted from the blood of healthy others -- while Tafasitamab is an anticancer antibody targeting CD19, a protein overexpressed explicitly in blood cancer.
    
    “The study found that the effect of each monotherapy was excellent. When combined, however, it could have a higher anticancer effect,” GC Labcell said. “Animal studies confirmed increased antibody-dependent cellular cytotoxicity (ADCC) compared to the monotherapy of each agent.”
    
    The study also found that the survival of co-administered groups with high ADCC was longer than that of single-administered groups, the company added. ADCC is a mechanism of action by which immune cells exert killing function on cancer cells and is known as an indicator of anticancer effects.
    
    “Our study identified the possibility of treating lymphoma patients who did not respond to antibody monotherapy,” said Hwang Yu-kyung, director of GC Labcell’s Cell Therapy Research Center. “We will speed up the development of next-generation therapeutics.”
    
    The two companies also applied for a global patent for its combination treatment in September.
    
    corea022@docdocdoc.co.kr